Denmark’s Zealand Pharma A/S has made a bid to acquire the assets of a US company in bankruptcy proceedings which, if approved, would give it a commercial footprint in the US diabetes market. The target company is Valeritas Holdings Inc which has an approved insulin delivery device in the US. The product, V-Go, is covered by Medicare and many commercial insurance plans.
